KORTUC

Executive Summary

KORTUC is a Japanese biotechnology company pioneering a novel approach to enhance cancer radiotherapy by targeting tumor hypoxia. Its lead candidate, KRC-01, is an intratumoral injection combining hydrogen peroxide and sodium hyaluronate. The treatment aims to reoxygenate hypoxic tumor regions, thereby increasing radiosensitivity and overcoming resistance in solid tumors. Currently in Phase I clinical development, KORTUC focuses on addressing a critical limitation of radiotherapy—hypoxia-induced radioresistance—which affects a significant proportion of cancer patients. The company's strategy leverages a well-established safety profile of its components, potentially accelerating clinical translation. Although still early-stage, KORTUC's technology could represent a meaningful addition to the radiotherapy armamentarium if clinical data demonstrate efficacy and manageable toxicity. KORTUC operates in the competitive space of radiosensitizers, where few approved options exist. Its unique mechanism of using hydrogen peroxide as a source of oxygen radicals distinguishes it from other hypoxia-targeting agents. The company has a lean team of 10-50 employees and is based in Tokyo, Japan. Given the Phase I stage, the immediate focus is on demonstrating safety and early signs of efficacy. Key upcoming catalysts include initial Phase I data, which could validate the approach and attract partnership interest. The company's private status and lack of disclosed funding suggest it may seek additional capital or strategic alliances to advance KRC-01 into later-stage trials.

Upcoming Catalysts (preview)

• Q1 2027Phase I clinical data readout50% success
• Q4 2026Strategic partnership or licensing deal30% success
• Q3 2026Grant or government funding announcement40% success